Orexigen Therapeutics, Inc. (OREX) Tops Q4 EPS by 3c; Updates on Contrave
Tweet Send to a Friend
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q4 EPS of ($0.41), $0.03 better than the analyst estimate of ($0.44). Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
